STAT+: RevMed’s pancreatic cancer drug nears European approval

🌐 STAT News Health (United States) —
STAT+: RevMed’s pancreatic cancer drug nears European approval

AI Summary

European regulators have recommended approval of Revolution Medicines’ Rasonque for pancreatic cancer, following its approval by the U.S. FDA. The recommendation moves the drug closer to availability in Europe.

Following a green light from the FDA, European regulators have now recommended the approval of Revolution Medicines' Rasonque for pancreatic cancer.

Health pancreatic cancer Rasonque Revolution Medicines drug approval FDA European regulators

Read original source →